This activity is hosted on the site of our educational partner

You will be connecting to our educational partner, which controls its own content, practices, and other policies.

You will be connecting to our educational partner, which controls its own content, practices, and other policies.

  • Overview
  • Pre-Assessment
  • Activity
  • Post-Test
  • Evaluation
  • Claim Credit
Clearing the Air in Severe Asthma Management: Improving Patient Outcomes Through Shared Clinical Decision Making

Clearing the Air in Severe Asthma Management: Improving Patient Outcomes Through Shared Clinical Decision Making



Time to Complete

1.50 hours


April 19, 2019


April 19, 2020
Add to Queue

Maximum Credits

1.50 / AMA PRA Category 1 CreditsTM

Accredited Provider

This activity is jointly provided by Global Education Group and Integritas Communications.

Commercial Supporter

This activity is supported by an educational grant from Sanofi Genzyme and Regeneron Pharmaceuticals.

Program Description/Statement of Need

This Interactive Exchange™ educational activity focuses on identification and long-term management of patients with severe asthma. Expert faculty will provide interpretive insights into the role of biomarkers, comorbidity management, and use of targeted biologic therapies, including their own clinical experience with personalizing therapy and engaging patients in shared decision making. Brief video segments will be shown throughout the program to highlight key aspects of severe asthma pathophysiology and the clinical implications for targeted therapies.

Intended Audience

The educational design of this activity addresses the needs of clinical immunologists, allergists, and other specialists involved in the management of patients with severe asthma.

Educational Objectives

Upon completion of this activity, participants will be better able to do the following:

  • Discuss asthma pathophysiology, including Th2-mediated processes and clinically relevant treatment targets
  • Implement guideline recommendations related to the identification, comprehensive assessment, and longitudinal management of patients with severe asthma
  • Describe the mechanistic rationale, published evidence, and prescribing considerations for biologic therapies in severe asthma
  • Tailor therapeutic regimens for patients with severe asthma based on disease phenotypes, ongoing symptoms and exacerbation risks, treatment-related toxicities, and comorbidities
  • Engage patients with severe asthma in long-term management planning to reflect treatment goals, clinical and laboratory findings, and potential benefits and risks of available therapeutic options

Conflict Of Interest Disclosure Policy

Global Education Group (Global) requires instructors, planners, managers and other individuals and their spouse/life partner who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by Global for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.


Jonathan Corren, MD
Associate Clinical Professor of Medicine and Pediatrics
David Geffen School of Medicine at UCLA
Director, Allergy Medical Clinic
Los Angeles, California

Dr. Corren discloses the following:
Speakers Bureau: AstraZeneca; Genentech, Inc.; Regeneron Pharmaceuticals, Inc., sanofi-aventis U.S. LLC
Consultant/Advisor: AstraZeneca; Genentech, Inc.; Regeneron Pharmaceuticals, Inc., sanofi-aventis U.S. LLC; Pulmatrix
Research Grant: AstraZeneca; Genentech, Inc.; Regeneron Pharmaceuticals, Inc.; sanofi-aventis U.S. LLC; Stallergenes Greer plc

John J. Oppenheimer, MD (Virtual Professor)
Clinical Professor of Medicine, Rutgers New Jersey Medical School
Newark, New Jersey
Clinician, Atlantic Health System
Morristown Medical Center
Morristown, New Jersey

Dr. Oppenheimer discloses the following:
Consultant/Independent Contractor: AstraZeneca; DBV Technologies; GlaxoSmithKline, Sanofi
Grant/Research Support (Adjudication Data and Safety Monitoring Board): AstraZeneca; Novartis

Reynold A. Panettieri, Jr, MD
Professor of Medicine, Robert Wood Johnson Medical School
Vice Chancellor, Translational Medicine and Science
Director, Rutgers Institute for Translational Medicine and Science
New Brunswick, New Jersey
Emeritus Professor of Medicine, University of Pennsylvania
Philadelphia, Pennsylvania

Dr. Panettieri has nothing to disclose.

Sally E. Wenzel, MD
Professor of Medicine and Immunology
Director, University of Pittsburgh Asthma Institute at UPMC/UPSOM
UPMC Chair of Translational Airway Biology
Chair, Department of Environmental and Occupational Health
Graduate School of Public Health
University of Pittsburgh
Pittsburgh, Pennsylvania

Dr. Wenzel discloses the following:
Consultant/Advisor: AstraZeneca; sanofi-aventis U.S. LLC; Pieris
Research Grant: AstraZeneca; GlaxoSmithKline; Novartis Pharmaceuticals Corporation (paid to University Pittsburgh Medical Center); Regeneron Pharmaceuticals, Inc., sanofi-aventis U.S. LLC

Planners' and Managers' Disclosures

The planners and managers reported the following financial relationships or relationships to products or devices they or their spouses/life partners have with commercial interests related to the content of this CME/CE activity:

Lindsay Borvansky has nothing to disclose.
Andrea Funk has nothing to disclose.
Ashley Cann has nothing to disclose.
Julia Muino has nothing to disclose.
Rose O’Connor, PhD, CHCP, has nothing to disclose.
Jim Kappler, PhD, has nothing to disclose.




AMA PRA Category 1 Credit(s)TM

Accreditation Statement

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Global Education Group (Global) and Integritas Communications. Global is accredited by the ACCME to provide continuing medical education for physicians.

This CME/CE activity complies with all requirements of the federal Physician Payment Sunshine Act. If a reportable event is associated with this activity, the accredited provider managing the program will provide the appropriate physician data to the Open Payments database.

Designation Statement

Global Education Group designates this enduring activity for a maximum of 1.50 AMA PRA Category 1 CreditsTM  .  Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration. Global and Integritas Communications do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.


Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Fee and Refund / Cancellation Policy

There is no fee for this educational activity.


In order to receive credit, participants must complete the preactivity questionnaire, post-test, and program evaluation. Participants must also score at least 66% on the post-test. Certificates will be distributed online at the conclusion of the activity. Your online certificate will be saved on myCME within your Profile/CME History, which you can access at any time.

For information about the accreditation of this program, please contact Global at 303-395-1782 or

If you have any other questions relating to your certificate or other issues with the activity, please contact

Privacy Policy


Hardware and Software Requirements
  • A computer with an internet connection
  • Internet Browser: Internet Explorer 7.x or higher, Firefox 4.x or higher, Safari 2.x or higher, or any other W3C standards compliant browser
  • Additional Software: Adobe Flash Player and/or an HTML 5 capable browser maybe required for video or audio playback. PowerPoint or Adobe Acrobat Reader may occasionally be required
Add to Queue